Argo Biopharma’s updated Phase 2 data show up to a 96% reduction in hereditary angioedema attacks with BW-20805, while plasma prekallikrein suppression remained substantial through Day 169.
Withings is launching StethO Sense for BeamO, combining FDA-cleared eMurmur heart-sound AI with a separate U.S. wellness breathing index from StethoMe.
InnovHeart has implanted its investigational Saturn transseptal mitral valve in the first U.S. patient as the CASSINI program reaches 15 treated patients globally.
The FDA has cleared Acepodia’s ACE723 IND, allowing the GPC3-targeted dual-payload antibody-drug conjugate to begin Phase 1 testing in unresectable or metastatic hepatocellular carcinoma.
AbbVie’s Phase 3 CERVINO trial met both primary endpoints as etentamig achieved a 74% response rate and reduced progression or death risk by 60% in heavily pretreated multiple myeloma.
FDA approves Etcamah after an ESR1 mutation is detected in blood before breast cancer progresses on scans, creating a first for ctDNA-guided treatment.
Two-year RESTORE results show sustained disability, pain and quality-of-life improvements with Mainstay Medical’s ReActiv8 restorative neurostimulation system for chronic low back pain.
The WHO has granted Emergency Use Listing to Cepheid’s one-hour Xpert Hemorrhagic Fever Panel for the Ebola Bundibugyo outbreak in the DRC, enabling use on existing GeneXpert systems.
eGenesis says five patients have received EGEN-2784 pig kidneys under Expanded Access, with three maintaining kidney function beyond eight months and two later receiving human donor kidneys.
Stoke Therapeutics and Biogen say four-year zorevunersen data show durable seizure reductions plus continuing cognitive and behavioral improvements as Phase 3 EMPEROR advances.